Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial) (NCT01696981) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial)
United States154,900 participantsStarted 1993-11-16
Plain-language summary
This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers. Screening tests may help doctors find cancer cells early and plan better treatment for colorectal cancer.
Who can participate
Age range55 Years – 74 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Exclusion Criteria:
* Men and women who at the time of randomization are less than 55 or greater than or equal to 75 years of age
* Individuals undergoing treatment for cancer at this time, excluding basal-cell and squamous-cell skin cancer
* Individuals with known prior cancer of the colon, rectum, lung, prostate
* This includes primary or metastatic PLCO cancers
* Individuals with previous surgical removal of the entire colon, one lung, or the entire prostate (men only)
* Until October 1996, women with previous surgical removal of both ovaries were excluded from the trial. In order to increase the enrollment of women into the trial, beginning in October 1996, these women were no longer excluded for this reason.
* Individuals who are participating in another cancer screening or cancer primary prevention trial
* Males who have taken Proscar/Propecia/finasteride in the past 6 months
* NOTE: Individuals who are already enrolled in the trial when their physician prescribes finasteride are not prevented from taking this medication. As a result, these participants will continue to be screened and followed just as those participants who are not on finasteride.
* NOTE: Men who are taking Tamoxifen are not excluded from any part of the PLCO Screening Trial.
* Prior to April 1, 1999 women were excluded from the trial if they were currently taking or had taken Tamoxifen or Evista\\Raloxifene in the past 6 months. As of April 1999 based on a decision from the PLCO Ovary Su…
What they're measuring
1
Colorectal Cancer Deaths
Timeframe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.1 years.
2
Colorectal Cancer Death Rates
Timeframe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.1 years.